OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye ...

Caused by bacterial infections or diseases such as keratoconus, thinning of the cornea can lead to blindness if not addressed. An experimental new injectable material could help keep that from ...

Annually in the U.S., about 40,000 people with corneal endothelial cell dystrophy receive a corneal transplant. The ligand of melanocortin MC1 receptor (MC1R) has been shown to protect the corneal ...

An injectable biomaterial activated by pulses of low-energy blue light has tremendous potential for on-the-spot repair to the domed outer layer of the eye, a team of University of Ottawa researchers ...